Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1

Interventions

Imatinib Mesylate 17Cytarabine 13Azacitidine 13Cyclophosphamide 11Decitabine 9Dasatinib 9Etoposide 8nilotinib 7Peripheral Blood Stem Cell Transplantation 7Busulfan 7Tacrolimus 6Polymerase Chain Reaction 6Idarubicin 6Antilymphocyte Serum 6fludarabine phosphate 5Mycophenolic Acid 5Melphalan 5Blood Specimen Collection 5ruxolitinib 4pegaspargase 4fludarabine 4Whole-Body Irradiation 4Radiotherapy 4Methylprednisolone 4Hydroxyurea 4Filgrastim 4ponatinib 3Surveys and Questionnaires 3Rituximab 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × lestaurtinib × Myeloid × Clear all
NCT00668421 2014-11-26

CEP-701 (Lestaurtinib) in Myelofibrosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Unknown
60 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡